NLS Pharmaceutics Announces Strategic Merger and Financing Milestones

NLS Pharmaceutics ( (NLSP) ) just unveiled an update.

On June 16, 2025, NLS Pharmaceutics announced significant milestones and future plans, including major financing events and a strategic merger with Kadimastem Ltd. The company completed equity financing transactions and secured a $25 million equity facility to support the merger and clinical programs. Positive clinical developments were reported, including preclinical data for AEX-2 and successful FDA meetings for Type 1 Diabetes treatment. The merger with Kadimastem, approved by both companies’ boards and shareholders, aims to create a Nasdaq-listed entity, NewcelX, with a robust pipeline in neurodegenerative diseases, diabetes, and CNS disorders. The merger is expected to enhance the company’s strategic position and provide comprehensive therapeutic options for patients.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. Founded in 2015 and headquartered in Switzerland, NLS collaborates with world-class partners and scientists to address unmet medical needs in rare and complex CNS disorders.

Average Trading Volume: 220,202

Technical Sentiment Signal: Sell

Current Market Cap: $8.2M

For a thorough assessment of NLSP stock, go to TipRanks’ Stock Analysis page.